Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) announced that CEO Rahul Ballal, Ph.D., will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, from 1:40-2:10 p.m. ET. This clinical-stage biotechnology company focuses on developing therapeutics for rare inherited genetic disorders of hemoglobin, particularly with its investigational drug IMR-687. A replay of the chat will be available on Imara's website under the 'Events and Presentations' section.

News Market Reaction – IMRA

+3.30%

+3.30% Session move

In the trading session that priced this news, IMRA gained 3.30%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, from 1:40-2:10 p.m. ET. 

A replay of the webcast will be archived on the “Events and Presentations” section of Imara’s website. 

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Media Contact:
Gina Nugent
Ten Bridge Communications
617-460-3579
gina@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com 

FAQ

What is the date and time of Imara's Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference?

The Fireside Chat will take place on February 26, 2021, from 1:40-2:10 p.m. ET.

Who will represent Imara at the Fireside Chat?

Rahul Ballal, Ph.D., President and CEO of Imara, will participate in the Fireside Chat.

What is IMR-687 developed by Imara?

IMR-687 is a highly selective, potent small molecule inhibitor of PDE9 aimed at treating sickle cell disease and beta-thalassemia.

Where can I find a replay of Imara's Fireside Chat?

A replay will be archived on the 'Events and Presentations' section of Imara's website.

What types of disorders does Imara focus on treating?

Imara specializes in developing treatments for rare inherited genetic disorders of hemoglobin.